New therapies for the management of keloids.
A broad range of therapeutics is currently available for the treatment of keloids, but none have been shown to be completely effective in flattening existing keloids, reducing associated symptoms or preventing recurrence. Therefore, newer treatments not routinely used for keloids have been examined more recently, including laser therapy, intralesional interferon and imiquimod, which have had variable success as therapies for keloids. This article briefly reviews such experimental data and presents recommendations for management of keloids as well.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D006801:Humans; D000077271:Imiquimod; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007369:Interferon Inducers / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007627:Keloid / Q000188:drug therapy* / Q000601:surgery*; D053685:Laser Therapy; D011994:Recombinant Proteins; D016559:Tacrolimus / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000634:Aminoquinolines; D007166:Immunosuppressive Agents; D007369:Interferon Inducers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000077271:Imiquimod; D016559:Tacrolimus